Utilization of Whole Exome Sequencing Data to Identify Clinically Relevant Pharmacogenomic Variants in Pediatric Inflammatory Bowel Disease

Daniel J. Mulder, MD, PhD1,2, Sam Khalouei, PhD3, Neil Warner, PhD1,2,4, Claudia Gonzaga-Jauregui, PhD5, Peter C. Church, MD1,2, Thomas D. Walters, MD1,2, Arun K. Ramani, PhD3, Anne M. Griffiths, MD1,2, Iris Cohn, MSc, RPh6 and Aleixo M. Muise, MD, PhD1,2,4,6

INTRODUCTION: We hypothesized that variants within clinically relevant pharmacogenes could be identified using a whole exome sequencing data set derived from a cohort of more than 1,000 patients with inflammatory bowel disease (IBD).

METHODS: Pediatric patients diagnosed with IBD underwent whole exome sequencing. We selected 18 genes with supporting literature where specific exonic variants would influence clinical care.

RESULTS: We identified actionable pharmacogenomic variants in 63% of patients. Importantly, 5% of patients with IBD were at risk for serious adverse effects from anesthesia and 3% were at increased risk for thrombosis.

DISCUSSION: We identified exonic variants in most of our patients with IBD that directly impact clinical care.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A449

Clinical and Translational Gastroenterology 2020;11:e00263. https://doi.org/10.14309/ctg.0000000000000263

INTRODUCTION
Pharmacogenomics presents a major opportunity to improve clinical care in a cost-effective manner for patients, especially those with complex diseases who often require a broad range of medications over the course of many years of living with disease. In pediatric inflammatory bowel disease (IBD), whole exome sequencing (WES) enables the genetic diagnosis of monogenic variants in a subset of patients (1). However, the collected WES data are underutilized and may also be used to identify loci or known variants important for drug metabolism and/or increased risk for adverse drug reactions (2,3). We hypothesized that exonic variants within clinically relevant pharmacogenes could be identified in a previously collected WES data set from a single-center cohort of more than 1,000 pediatric patients with IBD (1).

METHODS
Please see the Supplementary Materials section for detailed methodology.

Patients with IBD younger than 18 years and followed at the Hospital for Sick Children in Toronto had next generation WES, as previously described (1). We identified 18 pharmacogenes (see Supplementary Tables 1, Supplementary Digital Content 1, http://links.lww.com/CTG/A449 and 2) with relevance to patients with IBD (4). Gene selection was based on known pharmacogenomics guidelines including review of the Clinical Pharmacogenomics Implementation Consortium guidelines and those collected in the online Pharmacogenomics Knowledgebase (pharmgkb.org). We limited our search to pharmacogenomic variants that were covered in WES and for which precision therapy is recommended (through avoidance or altered dosing of medications).

Individual WES (n = 1,097, including pediatric patients and affected relatives with IBD) was aligned to the current reference genome (GRCh37) using the Genome Analysis Toolkit framework. Variants were called and annotated using Genome Analysis Toolkit version 3.6. Quality control measures were used to eliminate variant calls of poor quality (see Supplemental Material). Genome mining program GEMINI version 0.18 was used to identify variants of interest. Stargazer version 1.0, which uses the PharmVar database, was used to identify each patient’s star...
haplotype (a predefined pharmacogenomic designation for variant profiles that effect drug metabolism) for the genes of interest.

RESULTS

Our search strategy (see Supplementary Material, Supplementary Digital Content 1, http://links.lww.com/CTG/A449 and Figure 1) identified relevant exonic variants in 8 of the 18 pharmacogenes examined (Table 1) including clinically relevant variants applicable to IBD treatment with azathioprine in either TPMT or NUDT15 in 10% of our patients. Variants in cytochrome P450 pathway enzymes that are involved in metabolism of adjunct IBD therapies including antidepressant and pain medications were identified in the highest number of patients (58%). We also identified 3 patients with clinically actionable G6PD variants. Overall, we identified at least 1 actionable variant in 63% of patients in our cohort, and importantly, 5% of patients with IBD were at risk for serious adverse effects from anesthesia and 3% were at increased risk for thrombosis.

We did not identify any relevant exonic variants in HBA1/2 or HBB (thalassemia related anemia), RYR1 (anesthetic risk), or JAK2 (thrombosis risk) (see Supplemental Table 1, Supplementary Digital Content 1, http://links.lww.com/CTG/A449). The allele frequencies for our cohort were similar to those found in the general population, when we compared our samples with those in the Genome Aggregation Database (gnomAD) (5). We did not include in our final calculations patients with CYP2D6 variants that result in altered ondansetron/tropisetron metabolism, as the current Clinical Pharmacogenomics Implementation Consortium guideline recommendation is that these patients are not treated differently. Both ABCB1 and SLCO1B1 have been identified to contribute to methotrexate toxicity; given that no specific recommendations exist regarding these variants, we did not include them in our total actionable variant count but did include them in Supplemental Table (see Supplementary Digital Content 1, http://links.lww.com/CTG/A449).

DISCUSSION

We identified established pharmacogenomic variants that are currently recommended to necessitate alterations in pharmacologic or other medical management in most of our patients who underwent WES on a research basis to identify monogenic forms of disease. The findings of clinically actionable variants in such a large
portion of our cohort, although expected, is important because it demonstrates that genetics can be better used in clinical care.

Lifelong alterations to treatment based on next generation sequencing (NGS) has wide implications for improving the standard of care for patients with IBD. Currently, WES is most often performed in pediatric patients with IBD to identify rare damaging monogenic variants that are responsible for disease and may inform optimal therapy (1). Increasingly, targeted sequencing panels are being replaced with WES approaches, but with analysis initially limited to a few genes as a more cost effective strategy, a so-called “WES backbone” (6). Leveraging WES data for not only disease diagnosis but also pharmacogenomic applications would be cost effective and improve quality of life for patients with a number of pediatric conditions, including primary immunodeficiency, immune dysregulation, and other gastrointestinal disorders. However, it is worth considering that NGS techniques such as WES and whole genome sequencing (WGS) are not available to all. Targeted sequencing such as TPMT genotyping is more broadly used around the world. Future studies should evaluate the cost benefit of broad sequencing in patients with IBD because it can be considered a one-time test that can impact many aspects of care. It is also important to note that it is very likely that the value of NGS for a patient with IBD will increase over time as even more pharmacogenomic variants are linked to clinical care. The estimated one-time cost of WES and even WGS (7) is less than the estimated average cost of the first year of IBD care (8).

The drugs examined here have broad implications because pain medications are commonly used in IBD, and many patients have depression as a comorbidity. Patients with factor V Leiden are at increased risk for thrombotic events and are recommended to avoid estrogen-containing contraception (9). Genomics are also beginning

| Table 1. List of identified pharmacogenomic variants |
|---|
| **Utility category** | Gene | **Impacted drug or complication risk** | **Metabolizer/function status** | **No. of affected individuals** | **Percent of cohort** | **Clinical impact** | **Inheritance** |
| Direct IBD management | TPMT | Azathioprine (immunomodulator) | Intermediate | 66 | 6.02 | Increased risk of leukopenia, neutropenia, and myelosuppression | Complex multiallelic |
| | | Poor | 3 | 0.46 | Greatly increased risk of leukopenia, neutropenia, and myelosuppression | |
| | NUDT15 | Azathioprine (immunomodulator) | Intermediate | 42 | 3.83 | Increased risk of leukopenia, neutropenia, and myelosuppression | Complex multiallelic |
| | | Poor | 2 | 0.18 | Increased risk of leukopenia, neutropenia, and myelosuppression | |
| Adjunct IBD therapy | CYP2C19 | Citalopram, escitalopram, and sertraline (antidepressants) | Poor | 50 | 4.56 | Increased probability of side effects—arrhythmias, GI dysfunction, sexual dysfunction, and headache | Complex multiallelic |
| | CYP2D6 | Fluvoxamine and paroxetine (antidepressants) | Poor | 44 | 4.01 | Increased probability of side effects—arrhythmias, GI dysfunction, sexual dysfunction, and headache | Complex multiallelic |
| | | Venlafaxine complex multiallelic (antidepressant) | Intermediate | 325 | 29.63 | Increased probability of side effects—arrhythmias, GI dysfunction, sexual dysfunction, and headache | Complex multiallelic |
| | CYP2C9 | Codeine and tramadol (analgesic) | Poor | 53 | 4.83 | Treatment failure—insufficient pain control | Complex multiallelic |
| | | Poor | 44 | 4.01 | Increased risk of GI bleeding, hypertension, cardiac event, and renal damage | |
| General risk variants | F5 | Thrombosis risk | Leiden variant | 34 | 3.10 | Thrombosis risk | Intermediate |
| | G6PD | Hemolysis risk | Decreased | 1 | 0.09 | Hemolysis due to physiologic stress or drug interaction (including sulfasalazine) | X-linked |
| | CACNA1S | Anesthetic risk | Decreased | 53 | 4.83 | Hypokalemic periodic paralysis risk and malignant hyperthermia risk | Intermediate |

GI, gastrointestinal; IBD, inflammatory bowel disease.
to identify risk alleles potentially influencing response to biologics, including antitumor necrosis factor-α antibodies. The observations of a role for HLA-DQ haplotype in influencing the likelihood of development of antidrug antibodies could pave the way to personalized decision-making around choice of antitumor necrosis factor and necessity of combination therapy with an immunomodulator (10). However, a limitation of WES compared with WGS is that it does not reliably identify structural variants or noncoding regions; thus, these were not analyzed in our study. For example, the CYP2C19*17 variant allele (rs12248560 (c.-806C>T)) mapping to the promoter region that defines rapid metabolizers of proton pump inhibitors, antidepressants, voriconazole, and other drugs is not captured in standard WES (2,3). Nevertheless, mining WES data for pharmacogenomic variants still had clinical implications for most patients in our cohort, implying that the cost-benefit balance of WES and WGS still requires further consideration.

In conclusion, using exome data derived for other purposes, we identified pharmacogenomic variants in most of our patients that could immediately impact clinical care based on current guidelines. The identification of medically actionable pharmacogenomic variants could have an impact on care and medication prescription for the remainder of the patient’s life, especially when identified variants increase risk for serious adverse effects from anesthesia or thrombosis. These findings are not limited to pediatric IBD but would allow precision therapy of many pediatric and adult patients.

CONFLICTS OF INTEREST

Guarantor of the article: Aleixo M. Muise, MD, PhD.
Specific author contributions: Iris Cohn, MSc, RPh, and Aleixo M. Muise, MD, PhD, are the cosenior authors. D.J.M., S.K., I.C., and A.M.M.: study concept and design. D.J.M., S.K., P.C.C., T.D.W., A.M.G., and A.M.M.: acquisition of data. All authors: analysis and interpretation of data. D.J.M., S.K., N.W., I.C., and A.M.M.: drafting of the manuscript. All authors: critical revision of the manuscript for important intellectual content.
Financial support: A. M. Muise is funded by the Leona M. and Harry B. Helmsley Charitable Trust, a Canada Research Chair (Tier 1) in Pediatric IBD, Canada Institute of Health Research (CIHR) Foundation Grant and NIDDK (RC2DK118640) Grant. A. M. Griffiths hold the Northbridge Financial Corporation Chair in IBD at SickKids Hospital, University of Toronto. D. J. Mulder is funded by a CIHR-Canadian Association of Gastroenterology (CAG) Fellowship.
Potential competing interests: C. Gonzaga-Jauregui is a full-time employee of the Regeneron Genetics Center from Regeneron Pharmaceuticals and receives stock options as part of compensation. All other authors declare no competing interests.

ACKNOWLEDGMENTS

We thank the patients and their families and healthy individuals for participating in this study. We thank Karoline Fiedler for assistance with patient-related materials. Bioinformatics analyses were supported in part by the Canadian Center for Computational Genomics (C3G), part of the Genome Technology Platform (GTP) funded by Genome Canada through Genome Quebec and Ontario Genomics.

Study Highlights

WHAT IS KNOWN

✓ Patients with inflammatory bowel disease (IBD) require many medications.
✓ Many known genetic variants impact medication effect.

WHAT IS NEW HERE

✓ Actionable pharmacogenomic variants were found in most patients with (63%) IBD.
✓ Five percent were at risk for serious adverse effects from anesthesia, and 3% were at increased risk for thrombosis.

TRANSLATIONAL IMPACT

✓ Actionable pharmacogenomic variants could have immediate and long-term impact on care for many patients with IBD.

REFERENCES

1. Crowley E, Warner N, Pan J, et al. Prevalence and clinical features of inflammatory bowel diseases associated with monogenic variants, identified by whole-exome sequencing in 1000 children at a single center. Gastroenterology 2020;158:2208–20.
2. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526:343–50.
3. Cohn I, Paton TA, Marshall CR, et al. Genome sequencing as a platform for pharmacogenetic genotyping: A pediatric cohort study. NPJ Genom Med 2017;2:19.
4. Lučaño M, Franca R, Selvestrel D, et al. Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2018;14:1209–23.
5. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285–91.
6. Hayeems RZ, Bhawra J, Tsiplova K, et al. Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray. Eur J Hum Genet 2017;25:1303–12.
7. Schwarze K, Buchanan J, Taylor JC, et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med 2018;20(10):1122–30.
8. Park KT, Ehrlich OG, Allen JL, et al. The cost of inflammatory bowel disease: An initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis 2020;26(1):1–10.
9. Kujovič JL. Factor V Leiden thrombophilia. In: Adam MP, Ardinger HH, Pagon RA, et al (eds). GeneReviews. University of Washington, Seattle, WA, 1993.
10. Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab andadalimumab in patients with Crohn’s disease. Gastroenterology 2020; 158:189–99.

Open Access This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.